Effect of Auricular Stimulation on Locomotion in Patients With Parkinson's Disease

March 9, 2020 updated by: Inventram
The effect of auricular stimulation on the locomotion capability in patients with Parkinson's Disease was investigated.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Effect of the auricular stimulation as a supplementary and alternative usage to Levodopa was investigated in this study. Clinical data were collected through motion capture system while the participants performed the clinical task asked by the investigators.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
10

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • İstanbul, Turkey
        • Koc University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Diagnosis of Parkinson's Disease
  • H&Y Stage >= 1
  • Existing bradykinesia symptoms
  • Existence of one of the symptoms below
  • Resting Tremor
  • Rigidity
  • Walking disorder

Exclusion Criteria:

  • Cardiac Pacemaker
  • Psychiatric diagnosis
  • Irregular heart/respiration rate
  • Pregnancy
  • Alcohol consumption
  • Cardiovascular disease history
  • Wearing an electro-active prosthesis
  • Brain surgery history
  • Ongoing TENS/PENS therapy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: CROSSOVER
  • Masking: NONE

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
NO_INTERVENTION: Sole Medication
Monitoring under current prescribed medication
ACTIVE_COMPARATOR: Combined stimulation & medication
Concurrent usage of stimulation with the prescribed medication
Device: Percutaneous electrical nerve stimulation
Stimulation and medication at the same instant
Other Names:
  • Stimulation & Medication
Device: Percutaneous electrical nerve stimulation
Stimulation is given without administering medication
Other Names:
  • Stimulation Only
ACTIVE_COMPARATOR: Sole Stimulation
Alternating usage of stimulation to the prescribed medication
Device: Percutaneous electrical nerve stimulation
Stimulation and medication at the same instant
Other Names:
  • Stimulation & Medication
Device: Percutaneous electrical nerve stimulation
Stimulation is given without administering medication
Other Names:
  • Stimulation Only

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Stride length [m]
Time Frame: Time Frame: Baseline
Measurement through motion capture system
Time Frame: Baseline
Stride length [m]
Time Frame: Time Frame: 20 minutes after stimulation is initiated
Measurement through motion capture system
Time Frame: 20 minutes after stimulation is initiated
Stride length [m]
Time Frame: Time Frame: 40 minutes after stimulation is initiated
Measurement through motion capture system
Time Frame: 40 minutes after stimulation is initiated
Stride length [m]
Time Frame: Time Frame: 60 minutes after stimulation is initiated
Measurement through motion capture system
Time Frame: 60 minutes after stimulation is initiated
Stride velocity [m/s]
Time Frame: Time Frame: Baseline
Measurement through motion capture system
Time Frame: Baseline
Stride velocity [m/s]
Time Frame: Time Frame: 20 minutes after stimulation is initiated
Measurement through motion capture system
Time Frame: 20 minutes after stimulation is initiated
Stride velocity [m/s]
Time Frame: Time Frame: 40 minutes after stimulation is initiated
Measurement through motion capture system
Time Frame: 40 minutes after stimulation is initiated
Stride velocity [m/s]
Time Frame: Time Frame: 60 minutes after stimulation is initiated
Measurement through motion capture system
Time Frame: 60 minutes after stimulation is initiated
Turning Velocity [deg/s]
Time Frame: Time Frame: Baseline
Measurement through motion capture system
Time Frame: Baseline
Turning Velocity [deg/s]
Time Frame: Time Frame: 20 minutes after stimulation is initiated
Measurement through motion capture system
Time Frame: 20 minutes after stimulation is initiated
Turning Velocity [deg/s]
Time Frame: Time Frame: 40 minutes after stimulation is initiated
Measurement through motion capture system
Time Frame: 40 minutes after stimulation is initiated
Turning Velocity [deg/s]
Time Frame: Time Frame: 60 minutes after stimulation is initiated
Measurement through motion capture system
Time Frame: 60 minutes after stimulation is initiated
Double Support Percentage during walking [%]
Time Frame: Time Frame: Baseline, 20 minutes, 40 minutes, 60 minutes
Measurement through motion capture system
Time Frame: Baseline, 20 minutes, 40 minutes, 60 minutes
Double Support Percentage during walking [%]
Time Frame: Time Frame: 20 minutes after stimulation is initiated
Measurement through motion capture system
Time Frame: 20 minutes after stimulation is initiated
Double Support Percentage during walking [%]
Time Frame: Time Frame: 40 minutes after stimulation is initiated
Measurement through motion capture system
Time Frame: 40 minutes after stimulation is initiated
Double Support Percentage during walking [%]
Time Frame: Time Frame: 60 minutes after stimulation is initiated
Measurement through motion capture system
Time Frame: 60 minutes after stimulation is initiated
Swing Phase Percentage during walking [%]
Time Frame: Time Frame: Baseline
Measurement through motion capture system
Time Frame: Baseline
Swing Phase Percentage during walking [%]
Time Frame: Time Frame: 20 minutes after stimulation is initiated
Measurement through motion capture system
Time Frame: 20 minutes after stimulation is initiated
Swing Phase Percentage during walking [%]
Time Frame: Time Frame: 40 minutes after stimulation is initiated
Measurement through motion capture system
Time Frame: 40 minutes after stimulation is initiated
Swing Phase Percentage during walking [%]
Time Frame: Time Frame: 60 minutes after stimulation is initiated
Measurement through motion capture system
Time Frame: 60 minutes after stimulation is initiated
Stance Phase Percentage during walking [%]
Time Frame: Time Frame: Baseline, 20 minutes, 40 minutes, 60 minutes
Measurement through motion capture system
Time Frame: Baseline, 20 minutes, 40 minutes, 60 minutes
Stance Phase Percentage during walking [%]
Time Frame: Time Frame: 20 minutes after stimulation is initiated
Measurement through motion capture system
Time Frame: 20 minutes after stimulation is initiated
Stance Phase Percentage during walking [%]
Time Frame: Time Frame: 40 minutes after stimulation is initiated
Measurement through motion capture system
Time Frame: 40 minutes after stimulation is initiated
Stance Phase Percentage during walking [%]
Time Frame: Time Frame: 60 minutes after stimulation is initiated
Measurement through motion capture system
Time Frame: 60 minutes after stimulation is initiated

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Inventram

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Koç University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Yusuf O Cakmak, MD, PhD, Otago University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 1, 2017

Primary Completion (ACTUAL)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 1, 2018

Study Completion (ACTUAL)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
May 1, 2018

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 29, 2019

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 4, 2019

First Posted (ACTUAL)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 8, 2019

Study Record Updates

Last Update Posted (ACTUAL)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 10, 2020

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 9, 2020

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • Par-03

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings